TCF7L2

There are 34 papers on TCF7L2 in aging research: 2 trials and 17 observational studies in people, 5 in animals, 9 reviews. The newest story, Nov 9, 2026: “Advanced heart-kidney-metabolic stages share 90 genetic regions”.

Gene

34 papers study it12 findings

HGNCNCBI GeneTaxon

7 new papers in 30 daysSee all 34 papers on TCF7L2

At a glance

The findings reach people, from one lab or study. 7 independent labs in 6 countries.

“the transcription factor 7-like 2 (TCF7L2) rs7903146 T allele predicted increases in 2-h OGTT blood glucose (p = 0.039).”
The T allele of TCF7L2 rs7903146 is associated with decreased glucose tolerance after bed rest in healthy older adultsScientific reports2022doi:10.1038/s41598-022-10683-1

1 of its findings points the other way.

Mice and humans: a single group. Cells and worms or flies: nothing yet.
  • 7 independent labs in 6 countries
  • 1 finding against
  • Funders: National Institutes of Health and others
  • 4 of 10 findings with company ties
  • Human trial2
  • Humans17
  • Animals4
  • Model organisms1
  • In silico1

Effects

4

Body weight change

no changein humans1

1 study
  1. TCF7L2 showed no clear effect on body weight change in humans (T risk allele carriers during semaglutide challenge).

    Human trialT risk allele carriers during semaglutide challenge

Remyelination

upin mice1

1 study
  1. TCF7L2 increases remyelination in mice (shown by Tcf7l2 overexpression in demyelinated R6/2 mice).

    Animalsshown by Tcf7l2 overexpression in demyelinated R6/2 mice

Myelin gene expression

upin mice1

1 study
  1. TCF7L2 increases myelin gene expression in mice (shown by Tcf7l2 overexpression in demyelinated R6/2 mice).

    Animalsshown by Tcf7l2 overexpression in demyelinated R6/2 mice

Glycemic variability

no changein humans1

1 study
  1. TCF7L2 was not clearly linked with glycemic variability in humans (without diabetes).

    Humanswithout diabetes72-hour periodn = 235

More on Glycemic variability

Associations

7

Type 2 diabetes

downin humans1upin humans1

2 studies
  1. TCF7L2 is associated with type 2 diabetes in smokers.

    Humansin smokers

  2. TCF7L2 is associated with type 2 diabetes in humans (TCF7L2 TT carriage with high omega-3 intake) (∼42% reduction in odds).

    ReviewTCF7L2 TT carriage with high omega-3 intakehigh omega-3 intake

More on Type 2 diabetes

Hypertension

upin humans1

1 study
  1. TCF7L2 is associated with hypertension in humans (TCF7L2 rs7903146 CT genotype in Ghanaian clinic attendees) (aOR 2.15, 95% CI 1.06–4.37).

    HumansTCF7L2 rs7903146 CT genotype in Ghanaian clinic attendeesn = 203

More on Hypertension

Glycemic and weight outcomes

mixedin humans1

1 study
  1. TCF7L2 is associated with glycemic and weight outcomes in humans.

    ReviewGLP-1 receptor agonist treatment; findings preliminary, inconsistent, or not yet replicated

Gene expression

mixedin silico1

1 study
  1. TCF7L2 is associated with gene expression in silico.

    In silicoaorta

2-h post-load glucose

upin humans1

1 study
  1. TCF7L2 predicts 2-h post-load glucose in humans following 7 days of bed rest (p = 0.039).

    Human trialfollowing 7 days of bed rest7 dayn = 31

More on 2-h post-load glucose

2-hour oral glucose tolerance test blood glucose

upin humans1

1 study
  1. TCF7L2 predicts 2-hour oral glucose tolerance test blood glucose in humans following 7 days of bed rest (p = 0.03925).

    Human trialfollowing 7 days of bed rest7 daysn = 31

More on 2-hour oral glucose tolerance test blood glucose

Mean nocturnal glucose

upin humans1

1 study
  1. TCF7L2 is associated with mean nocturnal glucose in humans (without diabetes) (4.48 versus 4.67 mmol/L; p-value = 0.03).

    Humanswithout diabetes72-hour periodn = 235

More on Mean nocturnal glucose

Funding

2 grants since 2018

National Institute of Diabetes and Digestive and Kidney Diseases$2.5M

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 1Mar 2026: 3Apr 2026: 0May 2026: 2Jun 2026: 2Jul 2026: 1Aug 2026: 0Sep 2026: 2Oct 2026: 5Nov 2026: 320 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Advanced heart-kidney-metabolic stages share 90 genetic regions

In 391,836 UK Biobank participants, a 90-region genetic core spanned stages 2–4 of the syndrome, while stage 1 differed substantially.In 391,836 UK Biobank participants, a 90-region genetic core spanned stages 2–4 of the syndrome, while stage 1 differed substantially.

Genetic association · 391,836 peopleCardiovascular-kidney-metabolic syndrome

See all 34 papers on TCF7L2